Bioequivalence and Bioavailability Forum 20:38 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

FDA-Subject by formulation interaction (Switchability) [Regulatives / Guidelines]

posted by sudy - India, 2018-03-28 07:09  - Posting: # 18598
Views: 1,244

Dear all,

I have a discussion point regarding switchability criteria for methylphenidate 54mg tabs (specially). For lower strength, they have removed this criterion.

As per guideline, we have to meet the ABE criteria and additionally meet 95% UB for switchability.

Now, as we are doing a fully replicate study as suggested by OGD recommendation on methylphenidate, can we use RSABE approach in case if we get ISCV-reference > 30% for any one of the PK parameter Cmax or partial AUCs, instead of using 90% CI calculation to prove the bioequivalence?

The OGD recommendation did not discuss anything about this case, as we know that methylphenidate is not a HVD. But incase if we got CV-R more than 30%, can we apply RSABE?

Your suggestion will be highly appreciated.

Regards,
Sudy

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,782 posts in 4,002 threads, 1,256 registered users;
online 14 (0 registered, 14 guests [including 13 identified bots]).

[…] our greatest mistake would be to forget that data
is used for serious decisions in the very real world,
and bad information causes suffering and death.    Ben Goldacre

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed